Emergent BioSolutions (EBS) Stock Overview
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EBS Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Emergent BioSolutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.48 |
| 52 Week High | US$13.41 |
| 52 Week Low | US$4.02 |
| Beta | 2.05 |
| 1 Month Change | 36.39% |
| 3 Month Change | 109.75% |
| 1 Year Change | 36.84% |
| 3 Year Change | -37.47% |
| 5 Year Change | -86.48% |
| Change since IPO | 6.67% |
Recent News & Updates
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry
Oct 08
Improved Revenues Required Before Emergent BioSolutions Inc. (NYSE:EBS) Stock's 29% Jump Looks Justified
Aug 24Recent updates
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry
Oct 08Improved Revenues Required Before Emergent BioSolutions Inc. (NYSE:EBS) Stock's 29% Jump Looks Justified
Aug 24Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations
Aug 15Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50
Aug 10Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Jul 05Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Jun 20Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
May 11
Transformational Initiatives Will Optimize Medical Countermeasures And Operations
Strategic refocus on medical countermeasures and NARCAN Nasal Spray aims to maintain market leadership and drive revenue growth.Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Mar 26Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet
Mar 21Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues
Mar 20Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Mar 05There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise
Jan 22Emergent BioSolutions: Stock Is A Likely Winner In 2025
Jan 14Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Nov 09Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Nov 08Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Oct 28Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Oct 04Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Sep 16Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Aug 18Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Aug 02Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
Jul 15Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
May 10New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Shareholder Returns
| EBS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.1% | 3.1% | 0.5% |
| 1Y | 36.8% | 3.9% | 20.0% |
Return vs Industry: EBS exceeded the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: EBS exceeded the US Market which returned 20% over the past year.
Price Volatility
| EBS volatility | |
|---|---|
| EBS Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EBS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EBS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 900 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector.
Emergent BioSolutions Inc. Fundamentals Summary
| EBS fundamental statistics | |
|---|---|
| Market cap | US$655.45m |
| Earnings (TTM) | US$75.90m |
| Revenue (TTM) | US$788.90m |
Is EBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EBS income statement (TTM) | |
|---|---|
| Revenue | US$788.90m |
| Cost of Revenue | US$404.60m |
| Gross Profit | US$384.30m |
| Other Expenses | US$308.40m |
| Earnings | US$75.90m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 48.71% |
| Net Profit Margin | 9.62% |
| Debt/Equity Ratio | 113.8% |
How did EBS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 01:14 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emergent BioSolutions Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| Dana Flanders | Goldman Sachs |